收费全文 | 358499篇 |
免费 | 14477篇 |
国内免费 | 840篇 |
耳鼻咽喉 | 4968篇 |
儿科学 | 12754篇 |
妇产科学 | 9306篇 |
基础医学 | 47624篇 |
口腔科学 | 13499篇 |
临床医学 | 27330篇 |
内科学 | 71814篇 |
皮肤病学 | 8788篇 |
神经病学 | 25480篇 |
特种医学 | 15188篇 |
外国民族医学 | 123篇 |
外科学 | 49202篇 |
综合类 | 2452篇 |
现状与发展 | 1篇 |
一般理论 | 64篇 |
预防医学 | 33569篇 |
眼科学 | 7359篇 |
药学 | 23646篇 |
2篇 | |
中国医学 | 880篇 |
肿瘤学 | 19767篇 |
2022年 | 1759篇 |
2021年 | 3925篇 |
2020年 | 2646篇 |
2019年 | 3657篇 |
2018年 | 8006篇 |
2017年 | 7088篇 |
2016年 | 6418篇 |
2015年 | 8478篇 |
2014年 | 9389篇 |
2013年 | 10124篇 |
2012年 | 20030篇 |
2011年 | 15853篇 |
2010年 | 7881篇 |
2009年 | 8826篇 |
2008年 | 10709篇 |
2007年 | 11996篇 |
2006年 | 11555篇 |
2005年 | 19160篇 |
2004年 | 19725篇 |
2003年 | 14955篇 |
2002年 | 9031篇 |
2001年 | 9243篇 |
2000年 | 6675篇 |
1999年 | 10059篇 |
1998年 | 2072篇 |
1996年 | 1641篇 |
1992年 | 9418篇 |
1991年 | 9544篇 |
1990年 | 9596篇 |
1989年 | 9195篇 |
1988年 | 8496篇 |
1987年 | 8098篇 |
1986年 | 7711篇 |
1985年 | 6929篇 |
1984年 | 4819篇 |
1983年 | 3893篇 |
1979年 | 4713篇 |
1978年 | 2959篇 |
1977年 | 2252篇 |
1976年 | 1954篇 |
1975年 | 3003篇 |
1974年 | 3629篇 |
1973年 | 3263篇 |
1972年 | 3193篇 |
1971年 | 3136篇 |
1970年 | 2993篇 |
1969年 | 2899篇 |
1968年 | 2666篇 |
1967年 | 2530篇 |
1966年 | 2206篇 |
Introduction
In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.Methods
Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.Results
Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had “deteriorated” status and more had “improved” status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.Conclusions
These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population. 相似文献Material and methods: original research studies were searched from seven databases (MEDLINE, EMBASE, CENTRAL, CINAHL, SCOPUS, PEDro and PubMed). Subsequently, two independent reviewers screened the titles and abstracts followed by full-text reviews to assess the studies' eligibility.
Results: eleven studies met the inclusion criteria and had data abstracted and quality assessed. Methodology varied considerably and yet cognitive tasks resulted in the ΔO2Hb increasing in 8 of the 11 and ΔHHb decreasing in 8 of 8 studies that reported this outcome. The cognitive tasks from 10 of the 11 studies were classified as “Working Memory” and “Verbal Fluency Tasks”.
Conclusions: although, the data comparison was challenging provided the heterogeneity in methodology, the results across studies were similar. 相似文献